

Pattern of infection and antibiotic activity among *Streptococcus agalactiae* isolates from adults in Mashhad, Iran

Masoumeh Malek-Jafarian¹, Fatemeh-Sadat Hosseini*¹,
Abodol-Reza Ahmadi¹

Abstract

Background: One of the main causes of sexually transmitted diseases is *group B β-hemolytic streptococci* (GBS) multiplying in the genital tracts. Penicillin is the most common drug for the treatment of infections caused by these bacteria, but in patients suffering from Penicillin allergy, Erythromycin and Clindamycin are used as alternative therapeutic drugs against GBS. Recently, resistance to these drugs has been reported more often. In this study, efforts have been made to determine the prevalence and antibiotic resistance of GBS.

Methods: Modified Christie Atkins Munch-Petersen (CAMP) test was conducted on over 2400 samples of urine and discharge taken from vagina, urethra and prostate. The drug sensitivity was performed by double disk sensitivity tests to Bacitracin, Trimethoprim, and Sulfamethoxazole and then the resistant samples were investigated by E-test to determine the minimal inhibitory concentrations (MICs) value.

Results: Twenty-three vaginal and 10 urethral discharge, 27 urine and 6 prostatic secretion samples were GBS positive. The most symbiotic microorganisms with GBS were strains of *Enterococci* (90%), *Staphylococcus saprophyticus* (25%) and *Candida albicans* (6%). The disk diffusion method showed 18 cases with Penicillin resistance (MIC: 1.5 mg/ml).

Conclusion: Taken together, GBS carriers' rate in this study was found 20.65% (8.24% men and 12.4% women). Furthermore, findings showed high-level resistance to Erythromycin and Clindamycin.

Keywords: Antibiotic resistance, Genitourinary system, *Streptococcus agalactiae*, minimal inhibitory concentration (MIC)

Introduction

Group B β-hemolytic streptococci (GBS) is the main cause of blood infection and Meningitis in infants (1, 2). According to the statistics published by the World Health Organization (WHO), about 15-45% of women are affected by GBS in their genitourinary system (3, 4). Fifty percent of infants become infected before birth or during delivery. In such cases, nearly 1-2% of newborns will develop progressively severe complications such as meningitis (5). In addition, *Streptococcus agalactiae* may cause severe infections

in adults. Especially people with background diseases such as diabetes mellitus, malignant tumor, liver and kidney failure, immune deficiency such as acquired immunodeficiency syndrome (AIDS) are at the risk for GBS (6-9). Moreover, GBS increases the risk for sexual diseases; it can multiply in the male reproductive organs, particularly the urethra and prostate and then possibly lead to pneumonia and bacteremia (9). Penicillin is the well-known drug in the treatment of infections caused by GBS. However,

1: Department of Laboratory Medicine, School of Paramedicine, Mashhad University of Medical Sciences, Mashhad, Iran

*Corresponding author: Fatemeh-Sadat Hosseini; Tel: +98 51- 38827029; Fax: +98- 51- 37684082; E-mail: Hosseinif68@yahoo.com

Received: Jun 21, 2014; Accepted: Oct 10, 2014

for people who have an allergic reaction to Penicillin, Erythromycin and Clindamycin are prescribed for patients with GBS infections. Recently, a developing resistance to these drugs has been reported (10). The purpose of this study was to determine the prevalence of *S. agalactiae* in genitourinary system infections and its resistance to Erythromycin and Clindamycin.

Materials and Methods

Samples were obtained from individuals with the genitourinary system infection (aged 15-40 and over) referred to medical diagnostic laboratories in Mashhad (Iran). Human specimens for testing included urine (n=1687), discharge taken from the vagina (n=208), urethra (n=200) and prostate (n=205). At first, epithelial cells (ECs) and white blood cells (WBCs) were counted for all samples. Then, they were streaked over blood agar plates (5% sheep's blood) and incubated into a candle jar. The symbiotic relationship with *Enterococcus*, *Staphylococcus saprophyticus* and *Candida albicans* (11), and the GBS identification from clinical specimens were analyzed using bacitracin, catalase, CAMP and Gram stain tests (12, 13). Moreover, subsequent tests were performed to estimate different resistance levels of GBS to different antibiotics (Ampicillin, Penicillin, Clindamycin, Erythromycin, Amoxiclav, Ceftriaxone, Vancomycin, Amikacin, Gentamicin, Nalidixic acid and Kanamycin).

Clinical isolates of GBS on blood agar were suspended in standard saline inoculating on Mueller-Hinton agar plates. Then, two prepared disks of Trimethoprim and Sulfamethoxazole (Masc Co, UK) were placed on the plates and incubated overnight (14).

In parallel, minimal inhibitory concentration (MIC) values were measured by E-test method and interpreted as susceptible, intermediate or resistant (15). As described for disk diffusion, the inoculation was carried out in the plates, and then strips covered

by antibiotic carriers were applied to each plate. After overnight incubation, the MIC was reported at the intersection of growth inhibition zone with the strip.

Results

Table 1 shows the frequent GBS infections by gender representing 69.7% of women carrying GBS.

Clinical isolates from different sites distributed among different age groups are summarized in table 2. With routine identification tests, a total of 66 GBS isolates were characterized (27 Urine, 23 Vagina, 9 Urethra and 6 Prostate). The majority were from the collected samples of urine and vaginal discharge demonstrating 40.9% and 34.85%, respectively. Moreover, our findings indicated that specimens taken from the vagina were more infected with GBS in 26-35 years old (48%). Highest rate of GBS presence in urinary tract was reported among individuals over 40 years old (67%). For urethra and prostate secretion, this was ranged from 31 to 40 years old (40%). As shown in table 2, there was an abnormal increase in the number of WBCs and ECs in about 34% of GBS isolates.

It was observed that the most symbiotic interactions were occurring between GBS and *Enterococcus*, 90%, followed by *Staphylococcus saprophyticus*, 25.7% (Table 3).

Table 4 demonstrates sensitivity testing frequencies with Trimethoprim and Sulfamethoxazole. About 27% of infectious samples were resistant to Penicillin at MIC of 1.5 µg/ml. The percentage of GBS resistance to Clindamycin and Erythromycin were 20% and 24.5%, respectively, with the average MIC value of 0.01 µg/ml. Furthermore, the disk diffusion susceptibility to Amikacin, Gentamicin, Nalidixic acid and Kanamycin resulted in 100% resistance for all clinical isolates of GBS fully susceptible to Ampicillin, Amoxiclav and Ceftriaxone.

Table 1. The percentage of GBS carriers by gender.

Gender	Total patients (n)	GBS carrier n (%)
Female	1200	46 (69.7)
Male	1200	20 (30.3)

Table 2. Cell counts in obtained specimens and on site distributions among different age groups

Variable		Vagina (n)	Urine (n)	Urethra (n)	Prostate (n)
Age	15-20	2	3	-	-
	21-25	2	1	2	-
	26-30	6	2	1	2
	31-35	5	2	2	2
	36-40	4	1	2	1
	>40	4	18	3	1
White blood cells (WBCs)	0-5	17	18	3	5
	high	6	9	6	1
Epithelial cells (ECs)	2-4	9	25	4	5
	high	14	2	5	1

Table 3. The culture positivity rate of Group β -hemolytic streptococci (GBS) and its coexistence organisms.

Microorganism	Rate (%)
<i>Enterococcus specie</i>	60 (90)
<i>Staphylococcus aureus</i>	17 (25.76)
<i>Candida species</i>	4 (6.06)

Table 4. Sensitivity testing frequencies with Trimethoprim and Sulfamethoxazole.

Antibiotic	Susceptible (%)	Intermediate (%)	Resistant (%)
Ampicillin	100	0	0
Penicillin	72.7	0	27.3
Clindamycin	80.0	0	20.0
Erythromycin	75.5	0	24.5
Amoxiclav	100	0	0
Ceftriaxone	100	0	0
Vancomycin	86.5	10.5	3
Amikacin	0	0	100
Gentamicin	0	0	100
Nalidixic acid	0	0	100
Kanamycin	0	0	100

Discussion

A growing body of literature reported that the infection rate and the frequency of antibiotic resistance of GBS have increased in adults (16). Taking into account all studies to date, these different incidence rates well correlated with geography, age, gender and collection sites reveal serious reservations about performing the susceptibility test before prescribing any antibiotic therapy (17).

To elucidate the frequent sites in various age and gender groups and resistance rate of GBS, 2400 samples from clinical laboratories in Mashhad, Iran, were studied and patterns of the antibiotic activity were carried out by the disk diffusion susceptibility.

Of the 2400 specimens, vagina indicated a higher proportion of GBS infection (11.05%) among the rest of isolates. In previous studies the frequency of GBS collection from different sites has also predominated in vaginal swabs (15, 18, 19).

Surprisingly comparison of our findings with those from Iran or other countries disclosed that the

resistance rate of GBS to Clindamycin and Erythromycin were among ranges (4-43% for Clindamycin and 1.7-46% for Erythromycin) so far recorded (16). We detected lower resistant rate to Clindamycin than those to Penicillin and Erythromycin. Besides, GBS isolates showed full susceptibility against Ceftriaxone providing another alternative option for treating patients especially women with a penicillin allergy in our environment (20).

Our results highlight a rapid screening method for diagnosing GBS in women. In addition, Clindamycin and Ceftriaxone are suggested as alternative antibacterial against GBS.

Acknowledgements

The authors would like to thank Ms. Motahare Sadat Hosseini at Varastegan Institute for Medical Sciences (Mashhad, Iran) for her kind help improving the manuscript.

References

1. Wang JT, Hsueh PR, Sheng WH, Chang SC, Luh KT. Infected chylothorax caused by *Streptococcus agalactiae*: a case report. *J Formos Med Assoc.* 2000 Oct;99(10): 783-4.
2. Andersen JR, Christensen R, Hertel J. Clinical features and epidemiology of septicemia and meningitis in neonates due to *Streptococcus agalactiae* in Copenhagen County, Denmark: a 10 year survey from 1992 to 2001. *Acta Paediatr.* 2004 Oct; 93(10): 1334-9.
3. Picard FJ, Bergeron MG. Laboratory detection of group B *Streptococcus* for prevention of perinatal disease. *Eur J Clin Microbiol Infect Dis.* 2004 Sep;23(9): 665-71.
4. Foxman B, Gillespie B, Manning SD, Howard LJ, Tallman P, Zhang L, et al. Incidence and duration of group B *Streptococcus* by serotype among male and female college students living in a single dormitory. *Am J Epidemiol.* 2006 Mar; 163(6): 544-51.
5. American Academy of Pediatrics. Group B streptococcal infections. In: Pickering LK, editors. *Red Book: 2012 Report of the Committee on Infectious Diseases.* 29th ed. Elk Grove Village, Illinois: American Academy of Pediatrics; 2012. p. 680.
6. Tunkel AR. *Bacterial meningitis.* Philadelphia: Lippincott Williams & Wilkins; 2001.
7. Schuchat A. Epidemiology of group B streptococcal disease in the United States: shifting paradigms. *Clin Microbiol Rev.* 1998 Jul; 11(3):497-513.
8. Domingo P, Barquet N, Alvarez M, Coll P, Nava J, Garau J. Group B streptococcal meningitis in adults: report of twelve cases and review. *Clin Infect Dis.* 1997 Nov; 25(5):1180-7.
9. Frey MN, Ioppi AE, Bonamigo RR, Prado GP. *Streptococcus agalactiae* involved in the etiology of Sexually Transmitted Diseases. *An Bras Dermatol.* 2011 Nov-Dec; 86 (6): 1205-7.
10. Schoening TE, Wagner J, Arvand M. Prevalence of erythromycin and clindamycin resistance among *Streptococcus agalactiae* isolates in Germany. *Clin Microbiol Infect.* 2005 Jul; 11(7): 579-82.
11. Manuel FR, MacDonald SW, Embil JA. Prevalence of group B beta-hemolytic streptococci in the male urethra. *Scand J Infect Dis.* 1980; 12(1): 33-5.

12. Darling CL. Standardization and evaluation of the CAMP reaction for the prompt, presumptive identification of *Streptococcus agalactiae* (Lancefield group B) in clinical material. *J Clin Microbiol.* 1975 Feb; 1(2): 171-4.
13. Yajko DM, Lawrence J, Nassos P, Young J, Hadley WK. Clinical trial comparing bacitracin with strep-A-chek for accuracy and turnaround time in the presumptive identification of *Streptococcus pyogenes*. *J Clin Microbiol.* 1986 Sep; 24(3): 431-4.
14. Grace ME, Bushby SR, Sigel CW. Diffusion of trimethoprim and sulfamethoxazole from susceptibility disks into agar medium. *Antimicrob Agents Chemother.* 1975 Jul; 8(1): 45-9.
15. Al-Sweih N, Jamal M, Kurdia M, Abduljabar R, Rotimi V. Antibiotic susceptibility profile of group B streptococcus (*Streptococcus agalactiae*) at the Maternity Hospital, Kuwait. *Med Princ Pract.* 2005 Jul-Aug; 14(4): 260-3.
16. Hsueh PR, Teng LJ, Lee LN, Ho SW, Yang PC, Luh KT. High incidence of erythromycin resistance among clinical isolates of *Streptococcus agalactiae* in Taiwan. *Antimicrob Agents Chemother.* 2001 Nov; 45(11): 3205-8.
17. Rahbar M, Hajia M, Mohammadzadeh M. Urinary tract infections caused by group b streptococcus in adult women: survey of 11800 urine culture results. *Iran J Pathol.* 2012 Jun; 7(1): 32-7.
18. Hicks P, Diaz-Perez MJ. Patient self-collection of group B streptococcal specimens during pregnancy. *J Am Board Fam Med.* 2009 Mar-Apr; 22(2): 136-40.
19. El-Kersh TA, Al-Nuaim LA, Kharfy TA, Al-Shammery FJ, Al-Saleh SS, Al-Zamel FA. Detection of genital colonization of group B streptococci during late pregnancy. *Saudi Med J.* 2002 Jan; 23(1): 56-61.
20. Jannati E, Roshani M, Arzanlou M, Habibzadeh S, Rahimi G, Shapuri R. Capsular serotype and antibiotic resistance of group B streptococci isolated from pregnant women in Ardabil, Iran. *Iran J Microbiol.* 2012 Sep; 4(3): 130-5.